Health
Moderna doses first patients in COVID-19 vaccine booster trial – The Science Board
Moderna has dosed the first patients in its study of modified COVID-19 vaccines, designed to address the potential need for vaccine booster candidates.
The new candidate, messenger RNA (mRNA)-1273.351, encodes the prefusion stabilized spike protein of the SARS-CoV-2 variant B.1.351, first identified in South Africa, and is being assessed as a booster vaccine to increase the response to emerging SARS-CoV-2 variants. The company is also investigating a second, multivalent candidate, mRNA-1273.211, that is a combination of mRNA-1273 and mRNA-1273.351.
Through a phase II clinical trial amendment, the company will enroll 60 participants previously vaccinated…
-
Noosa News15 hours agoCommissioner thanks police officer who threw a speed radar at a car
-
Noosa News13 hours agoNo matter what happens in his Origin debut, history beckons for rookie maroon Robert Toia
-
Noosa News22 hours agoDifficult to diagnose and potentially deadly — this lesser-known disease is becoming more common
-
Noosa News20 hours agoBrisbane news live: Federal fund for council’s cyclone clean-up dries up